Status and phase
Conditions
Treatments
About
This is a prospective, single site, randomized, double-blind Phase III clinical trial to evaluate the clinical value of Traditional Chinese Medicine in the adjuvant therapy of triple-negative breast cancer patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
200 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
ZhiMin Shao, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal